CASI PHARMACEUTICALS, INC. (CASIF) Total liabilities 2021–2025
CASI PHARMACEUTICALS, INC. (CASIF) total liabilities at each fiscal year-end, per SEC filings.
$62.9MFY2025 · since FY2021: $30.3M → $62.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $62.9M | +21.4% |
| FY2024 | $51.8M | +1.4% |
| FY2023 | $51.1M | +74.4% |
| FY2022 | $29.3M | -3.4% |
| FY2021 | $30.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CASIF financial trends
CASIF RevenueCASIF Net incomeCASIF Net marginCASIF Gross profitCASIF Gross marginCASIF Operating incomeCASIF Operating marginCASIF Operating cash flowCASIF Free cash flowCASIF Capital expendituresCASIF Return on equityCASIF Stock buybacksCASIF Dividends paidCASIF Total assetsCASIF Shareholders’ equityCASIF overview →